Aster Guardians Global Nursing Award Worth US $250,000 Now Open for Nominations From Nurses Worldwide
29.11.2021 09:00:00 EET | Business Wire | Press release
Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognize the phenomenal contribution of nurses to the healthcare delivery system globally, Aster Guardians Global Nursing Award has started receiving applications from nurses worldwide. The application system is completely online via www.asterguardians.com, where a nurse can submit her own application for the award or anyone can nominate a nurse, who they think is worthy of the award.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211128005220/en/
Aster has appointed Ernst & Young LLP (EY) as ‘Process Advisors’ who would ensure due-diligence of applications based on the defined eligibility criteria, evaluation of the entries by an independent panel of experts, and presentation by the finalists to an independent well-known Jury to determine the final winner.
Encouraging nurses from around the world to apply and nominate nurses for the award, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “Nurses are the unsung heroes of the healthcare system which has been proven undoubtedly during the Covid-19 pandemic. They continue to play a pivotal role and are the backbone of the healthcare delivery system working under tremendous pressure with huge commitment. Aster Guardians Global Nursing Award is our effort to recognize the phenomenal work being done by the nursing community worldwide. With over 7000 nurses in the Group, we consider it our obligation to recognize and celebrate the contribution of nurses across the world.”
Aster Guardians Global Nursing Award has started receiving nominations from nurses based in Middle East, Indian sub-continent, Africa, North and South America, Central Asia, Europe and Oceania. The last date for accepting nominations is 30th January, 2022, post which the review process will start. After the initial review based on the set criteria, shortlisted nominations will undergo a voting process. Subsequently 10 finalists would be selected for the award ceremony, interview, and interactions with the jury. The final Aster Guardian Global Nursing Award winner will be announced on 12th May- International Nurses Day in 2022 at a grand ceremony in Dubai. Apart from the substantial First Prize of US $ 250,000, the 9 finalists will also be presented with monetary prize and awards.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare through our 27 hospitals, 117 clinics and 225 pharmacies in seven countries, including India. We have over 23,100 plus dedicated staff including 3,029 doctors and 6,729 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: “We’ll treat you well.” We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.
DISCLAIMER:
Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Aster DM Healthcare will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
*Source: (AETOSWire)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211128005220/en/
Contact information
Lavanya Mandal
Head of PR and Internal Communications
Aster DM Healthcare
Tel: +971 528126577
Email: lavanya.mandal@asterdmhealthcare.com
Bejoy Changarath
Assistant General Manager - PR & Media Relations
Aster DM Healthcare
Tel: +971 524073559
Email: bejoy.changarath@asterdmhealthcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company Sign a 3.2 billion SAR Joint Venture Agreement to Develop and Deliver Expo Village14.9.2026 12:42:00 EEST | Press release
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh. The agreement represents the first joint venture milestone for Expo 2030 Riyadh and reinforces itscommitment to partnering with the private sector to unlock economic opportunities and create lasting value, both in the lead-up to the Expo and well beyond the event itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914576734/en/ Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh The Expo Village will provide purpose-built accommodation for Official Participants and delegations within a fully integrated sustainable district. Designed to
Motive Announces Entitlement Server General Availability for iPhone Duo, iPhone 18 Pro and iPhone 18 Pro Max14.9.2026 12:00:00 EEST | Press release
Motive, a global leader in mobile device and connectivity management, today announced the general availability of Motive Entitlement Server support for iPhone Duo and the iPhone 18 series. Ahead of Apple’s announcement, Motive invested in the platform capabilities needed to support the new devices at launch. As a result, operators can support the new iPhone product families without waiting for additional platform development. The release provides comprehensive support for entitlement applications aligned with GSMA standards and interoperates with iOS and Android device ecosystems. This includes iPhone Handoff, which lets customers of supported carriers switch seamlessly between two iPhones while using a single phone number. “Apple’s latest announcement marks another important step toward an eSIM-first future,” said Jeevithan Muttu, SVP and General Manager of Device Management at Motive. “We invest early and work closely across the device ecosystem so operators can support new experienc
Venture Global and China Gas Announce New Long-Term LNG Agreement14.9.2026 11:30:00 EEST | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects," said Venture Global CEO Mike Sabel. “We are pleased to deepen our long-standing partnership with Venture Global through this new agreement,” said Mr. Liu Ming Hui, Chairman and President of China Gas. “It further strengthens our portfolio
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom